CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space.

芝加哥--（商业新闻短讯）--人工智能和精准医学领域的领导者Tempus AI，Inc.（纳斯达克：TEM）今天宣布，其多模式免疫特征评分（IPS）算法测试现在仅可用于研究（RUO）。IPS是Tempus开发的第一个更大的基于免疫疗法的投资组合，旨在将下一代算法诊断引入免疫肿瘤学领域。

Additionally, Tempus is collaborating with other partners, like Cleveland Clinic, to bring additional immunotherapy-focused algorithmic tests to this growing portfolio, leveraging clinical, laboratory, genomic, and transcriptomic data to identify patients that may respond to immunotherapy..

此外，Tempus正在与克利夫兰诊所（Cleveland Clinic）等其他合作伙伴合作，利用临床，实验室，基因组和转录组数据来识别可能对免疫疗法有反应的患者，为这一不断增长的投资组合带来更多以免疫疗法为重点的算法测试。。

Tempus’ IPS is a pan-cancer, laboratory developed test (LDT) that assesses a combination of immunotherapy-related biomarkers from prior DNA and RNA test results to calculate an IPS from 0-100 and a classification of either IPS-Low or IPS-High. IPS results can support patient stratification across pan-cancer cohorts to help inform who may or may not respond to immunotherapy.

Tempus的IPS是一种泛癌实验室开发的测试（LDT），该测试评估了来自先前DNA和RNA测试结果的免疫治疗相关生物标志物的组合，以计算0-100的IPS以及IPS低或IPS高的分类。IPS结果可以支持泛癌队列中的患者分层，以帮助告知谁可能对免疫治疗有反应或可能没有反应。

The IPS test is available today to life sciences partners for research use only, and is intended to be available as an add-on option for clinicians ordering Tempus’ xT and xR at the end of the year. Tempus is performing a retrospective, real-world study to evaluate the prognostic and the predictive utility of IPS in advanced pan-cancer patients treated with immune checkpoint inhibitors (ICI) and will be releasing data later this year..

IPS测试今天仅可供生命科学合作伙伴用于研究用途，并计划作为附加选项，供临床医生在年底订购Tempus的xT和xR。Tempus正在进行一项回顾性的现实研究，以评估IPS在接受免疫检查点抑制剂（ICI）治疗的晚期泛癌患者中的预后和预测效用，并将于今年晚些时候发布数据。。

In addition to developing and launching IPS, Tempus has licensed a machine-learning-based algorithmic test developed by Timothy A. Chan, MD, PhD, Cleveland Clinic. As described in Nature Biotechnology, the test demonstrates an ability to predict the efficacy of immune checkpoint blockade based on patient-specific biological, laboratory, genomic, and clinical factors, and adds to our expanding immunotherapy specific biomarker portfolio..

除了开发和推出IPS之外，Tempus还许可了克利夫兰诊所医学博士Timothy a.Chan开发的基于机器学习的算法测试。如Nature Biotechnology所述，该测试证明了基于患者特异性生物学，实验室，基因组和临床因素预测免疫检查点阻断效果的能力，并增加了我们不断扩大的免疫疗法特异性生物标志物组合。。

'Immune checkpoint inhibitors continue to have an incredible impact on patient outcomes, and we are excited to continue building a portfolio of AI-enabled diagnostics and tools to better equip clinicians in understanding which patients may benefit from these kinds of therapies,” said Halla Nimeiri, MD, Chief Development Officer at Tempus.

Tempus首席开发官Halla Nimeiri医学博士说：“免疫检查点抑制剂继续对患者的预后产生令人难以置信的影响，我们很高兴继续建立一系列人工智能诊断和工具，以更好地帮助临床医生了解哪些患者可能从这些疗法中受益。”。

“The IPS test is our first multimodal algorithm to be introduced in the immunotherapy space, and we are excited to advance this field by providing critical insights that inform patient care.”.

“IPS测试是我们在免疫治疗领域引入的第一个多模式算法，我们很高兴通过提供关键的见解来推进这一领域，为患者护理提供信息。”。

“It’s a great pleasure to collaborate with Tempus on developing artificial intelligence powered models for better identification of patients who may respond to cancer immunotherapies,” said Timothy A. Chan, MD, PhD, Department Chair of Immunotherapy and Precision Oncology and Professor of Medicine at Cleveland Clinic.

克利夫兰诊所（Cleveland Clinic）免疫治疗和精准肿瘤学系主任、医学博士Timothy a.Chan说：“很高兴与Tempus合作开发人工智能驱动的模型，以更好地识别可能对癌症免疫疗法有反应的患者。”。

“We look forward to working together with Tempus to bring multimodal immunotherapy response prediction assays to patients.”.

“我们期待着与Tempus合作，为患者带来多模式免疫治疗反应预测分析。”。

Tempus’ AI-enabled platform generates the type of rich multimodal data required to develop a novel class of predictive algorithms that can be introduced in the clinic to support personalized patient treatment selection. The IPS and Cleveland Clinic immune response tests joins a growing suite of algorithmic tests offered by Tempus, including Homologous Recombination Deficiency (HRD), Tumor Origin (TO), dihydropyrimidine dehydrogenase (DPYD), and PurISTSM.

Tempus的AI支持平台生成了开发一类新型预测算法所需的丰富多模式数据类型，这些算法可以在临床中引入，以支持个性化的患者治疗选择。IPS和克利夫兰诊所免疫反应测试加入了Tempus提供的越来越多的算法测试，包括同源重组缺陷（HRD），肿瘤起源（TO），二氢嘧啶脱氢酶（DPYD）和嘌呤。

Each of these tests is designed to predict specific biological signals or clinical endpoints, ultimately supporting clinicians and life science partners as they seek to make more informed decisions for patients..

这些测试中的每一项都旨在预测特定的生物信号或临床终点，最终支持临床医生和生命科学合作伙伴为患者做出更明智的决定。。

For more information on IPS, reach out to Tempus at tempus.com/contact-us.

有关IP的更多信息，请访问Tempus.com/contact-us联系Tempus。

About Tempus

关于Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Tempus是一家通过人工智能在医疗保健中的实际应用来推进精准医学的技术公司。Tempus拥有世界上最大的多模式数据库之一，并拥有一个可访问和有用的操作系统，为医生提供支持AI的精准医学解决方案，以提供个性化的患者护理，同时促进最佳治疗方法的发现，开发和交付。

The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com..

目标是通过为医生提供工具，让每位患者在公司收集更多数据时学习，从而从之前的其他患者的治疗中受益。有关更多信息，请访问tempus.com。。

Forward Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties.

本新闻稿包含经修订的《1933年证券法》（“证券法”）第27A节和经修订的《1934年证券交易法》第21E节所指的有关Tempus和Tempus行业的前瞻性声明，涉及重大风险和不确定性。

All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of IPS and other tests, the indicated use of the IPS and other tests for potential clinical use, and the timing of the availability of such testing.

除本新闻稿中包含的历史事实声明外，所有声明均为前瞻性声明，包括但不限于有关IPS和其他测试的潜在影响，IPS和其他测试潜在临床用途的指示用途以及此类测试可用性的时间。

In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions.

在某些情况下，您可以识别前瞻性陈述，因为它们包含诸如“预期”、“相信”、“沉思”、“继续”、“可能”、“估计”、“预期”、“将要”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将要”或“将要”之类的词语，或这些词语或其他类似术语或表达的否定词。

Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release..

Tempus提醒您，上述内容可能不包括本新闻稿中的所有前瞻性声明。。

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects.

你不应该把前瞻性陈述当作对未来事件的预测。Tempus在本新闻稿中所载的前瞻性声明主要基于其对未来事件和趋势的当前预期和预测，它认为这些事件和趋势可能会影响Tempus的业务、财务状况、经营成果和前景。

These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Final Prospectus filed with the Securities and Exchange Commission (“SEC”) on June 17, 2024, pursuant to Rule 424(b)(4) under the Securities Act, as well as in other filings Tempus may make with the SEC in the future.

这些前瞻性报表存在与以下相关的风险和不确定性：Tempus的财务业绩；吸引和留住客户和合作伙伴的能力；管理Tempus的增长和未来支出；竞争和新市场进入者；遵守新的法律、法规和执行行动，包括人工智能领域任何不断发展的法规；维护、保护和增强Tempus知识产权的能力；吸引和留住合格团队成员和关键人员的能力；偿还或再融资未偿债务或获得额外融资的能力；未来收购、资产剥离或投资；气候变化、自然灾害、健康流行病、宏观经济状况、战争或其他武装冲突的潜在不利影响，以及Tempus于2024年6月17日向证券交易委员会（“SEC”）提交的最终招股说明书中标题为“风险因素”的一节中描述的风险、不确定性和其他因素，根据《证券法》第424（b）（4）条以及Tempus未来可能向SEC提交的其他文件。

In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press releas.

此外，本新闻稿中包含的任何前瞻性声明均基于Tempus认为截至目前合理的假设。Tempus没有义务更新任何前瞻性声明，以反映本新闻稿发布日期后的事件或情况。